Calavo Growers, Inc. Announces Third Quarter and Nine-Month Period Ended July 31, 2025 Financial Results
1. CVGW's Q3 sales at $178.8 million, down 1% year-over-year. 2. Fresh segment sales declined 5%, impacted by FDA detention costs. 3. Prepared segment sales surged 40%, indicating strong demand and efficiency. 4. Net income fell to $4.7 million from $5.4 million in prior year. 5. Legal resolution of FCPA inquiry may boost future operations.